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Draft recommendations by the National Institute for Health and
Care Excellence (NICE) did not recommend prescription of
unlicensed cannabis based products to patients on the NHS.1
The potential benefits for people with chronic pain were
considered too small relative to costs, and the quality of evidence
was rated too low to recommend use in children with severe
treatment resistant epilepsy.1 At present, the only way to get
cannabis products for medicinal use in the UK is through
prescriptions issued by private clinics2 (which are prohibitively
expensive) or the illicit market (which carries risk of prosecution
as well as unknown product content, quality, and safety). Given
the vocal requests for access to these products from patients and
their carers,3 stronger evidence is urgently needed so that these
products can be made available in situations where they are
known to be effective and safe.
Cannabis based medicines vary in their content of
Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which
have contrasting mechanisms of action, efficacy, and safety.4
Some cannabis based medicines include both THC and CBD,
which can interact with each other.5 Although evidence from
randomised controlled trials is stronger for certain formulations
(such as CBD for severe treatment resistant epilepsy4), patients
have expressed a preference for treatments such as THC
combined with CBD.3 Gathering evidence for such treatments
is a priority and can be expedited by using alternative trial
designs and patient registries.
Alternative trial designs and patient
registries
To compare varied cannabis based products efficiently,
randomised controlled trials can follow adaptive designs.6 For
example, patients can be initially randomised to one of several
treatment arms such as THC, CBD, or THC combined with
CBD. Interim analysis can eliminate treatment arms with poor
efficacy or safety at an early stage, while randomisation
continues to trial arms testing potentially effective doses.
Cannabis based products have been investigated for a wide
range of medical indications, some of which may share
aetiologies related to the endocannabinoid system.7 When
multiple disorders are characterised by the same underlying
mechanism, basket trials can investigate a single targeted
intervention across multiple diagnostic categories.8 Alternatively,
when different mechanisms are known to give rise to a common
medical diagnosis, umbrella trials can stratify patients into
different treatment arms based on the underlying disease
mechanism, allocating targeted interventions to each group.8
Stratification can also occur at the level of the individual patient.
N-of-1 trials allow randomised, double blind crossover
comparisons of active and control treatments in a cyclical
manner sequentially in the same patient.9 These trials can
establish efficacy and safety within an individual, and the results
from multiple patients can be combined with meta-analysis.
Such trials have been used to evaluate cannabis based products
in people with chronic pain10 and could be used for other
indications such as severe treatment resistant epilepsy. They
are ideally suited to situations such as treatment for
compassionate reasons, unlicensed use, and for patients who
fail to respond to conventional treatments,11 as is often the case
for cannabis based medicines. Establishing individual patients
as “responders”9 by using n-of-1 trials could provide evidence
strong enough to justify continued prescription.
Randomised controlled trials are not the only source of evidence.
The European Medicines Agency and the US Food and Drug
Administration have approved many drugs without randomised
trials.12 Other sources of evidence used to support drug approvals
include historical control studies and observational studies.12
Where cannabis based medicines are provided on private
prescription,2 patient registries should be set up to generate
observational data on real world clinical practice and outcomes.
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Such data can be rapidly obtained at minimal cost and may be
combined with registries outside the UK—in countries such as
Canada and Israel.
Need for industry cooperation
Initial public funding to support research into cannabis based
products has been offered through dedicated calls from the
National Institute for Health Research. However, the UK’s
parliamentary health and social care committee has raised
concerns about the unwillingness of industry to provide cannabis
based products for research13 or to support or conduct clinical
trials on their products. Greater support from industry could
increase access to cannabis based products in a research context
and help patients avoid the excessive costs of private
prescriptions.2 Providing access to cannabis based products in
trials with informed consent can offer participants balanced
information on the possible benefits and risks, which are
uncertain based on the evidence at present.
The current limited evidence for cannabis based products
alongside clear patient demand requires new solutions. Further
trials are urgently needed, and designs such as n-of-1 trials can
provide rapid evidence to inform treatment and optimise clinical
outcomes for individual patients.9 Like all research methods,
randomised trials have their limitations, such as poor
generalisability. Data should also be sought from alternative
methods, such as observational data from patient registries,
which can be triangulated with other findings to develop a robust
evidence base.14
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